Eli Lilly’s stock tumbles as Mounjaro, Zepbound sales miss by wide margins

Eli Lilly’s stock heads for biggest selloff since 2008 after sales of anti-obesity drugs Mounjaro and Zepbound came up well short of forecasts.



Source link